A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Public ClinicalTrials.gov record NCT03372057. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Study identification
- NCT ID
- NCT03372057
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SecuraBio
- Industry
- Enrollment
- 156 participants
Conditions and interventions
Conditions
Interventions
- Duvelisib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 21, 2018
- Primary completion
- Dec 21, 2023
- Completion
- Dec 21, 2023
- Last update posted
- Mar 6, 2025
2018 – 2023
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | — |
| University of California - Irvine | Irvine | California | 92691 | — |
| University of California - Los Angeles | Los Angeles | California | 90404 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Northwestern University - Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| University of Maryland | Baltimore | Maryland | 20742 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10021 | — |
| University of Rochester | Rochester | New York | 14627 | — |
| Stony Brook Cancer Center | Stony Brook | New York | 11794 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Novant Health | Charlotte | North Carolina | 28204 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| The Ohio State University | Columbia | Ohio | 43202 | — |
| Toledo Cancer Center | Toledo | Ohio | 43623 | — |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Baylor Research Institute - Charles Sammons Cancer Center | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03372057, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 6, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03372057 live on ClinicalTrials.gov.